Abbott Labs

Valuation Analysis

About the Company

Abbott Labs en bref

Abbott Labs (ABT) is currently trading at 77,16 € with a market capitalization of 134,4 Md €. The trailing P/E ratio stands at 24.77x, with a forward P/E of 14.59x. The 52-week range spans from 71,53 € to 121,35 €; the current price is 36.4% below the yearly high. Year-over-year revenue growth stands at +7.8%. The net profit margin stands at 13.9%.

💰 Dividende

Abbott Labs currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

24 analystes évaluent Abbott Labs (ABT) au consensus : Acheter. L'objectif de cours moyen est de 101,70 €, soit un potentiel de +31.81% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 80,29 € à 117,81 €.

Abbott Labs : la thèse d'investissement en détail

Abbott Labs (ABT) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Wall Street consensus sits at Buy with an average price target implying roughly 31.81% upside from current levels — analyst sentiment is firmly constructive.

Valorisation en contexte

The PEG ratio at 1.34 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric.

À surveiller

• The forward P/E of 14.59x is meaningfully below the trailing 24.77x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 31.81% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to relatively defensive market behavior.

Trading Data

Related Stocks in the Same Sector

Where can I buy Abbott Labs?

Compare top-rated brokers — low fees, trusted providers, fully regulated.